Within gliomas, those with a wildtype IDH-status were more common (n = 35, 53.8%, histopathologically defined glioblastomas, WHO grade IV), followed by those with a mutated IDH-status (n = 17, 26.2%, histopathologically defined as diffuse and anaplastic astrocytoma, WHO grades II and III respectively) and lastly there were n = 13 patients with a mutated IDH-status combined with a codeletion of 1p/19q (LOH, 20%, histopathologically defined as oligodendrogliomas WHO grades II and III), Table S2. This evidence concerns the gene IDH1 and central nervous system cancer.